Liang Song1, Shun Yao1, Di Zheng2, Yongli Xuan2, Wenhua Li3,4. 1. Institute of Cardiovascular Diseases, Xuzhou Medical University, Xuzhou, 221000, China. 2. Department of Cardiology, The Affiliated Hospital of Xuzhou Medical University, No.99 Huaihai West Road, Xuzhou, 221002, Jiangsu, China. 3. Institute of Cardiovascular Diseases, Xuzhou Medical University, Xuzhou, 221000, China. xzwenhua0202@163.com. 4. Department of Cardiology, The Affiliated Hospital of Xuzhou Medical University, No.99 Huaihai West Road, Xuzhou, 221002, Jiangsu, China. xzwenhua0202@163.com.
Abstract
OBJECTIVE: To explore the protective effect and mechanism of astaxanthin on the kidney of rats with contrast-induced acute kidney injury. METHODS: Forty SD rats were randomly divided into five groups: Control group (CON); Astaxanthin control group (AST); Contrast media group (CM); Astaxanthin pre-treatment group (AST + CM); N-acetylcysteine pre-treatment group (NAC + CM), each group with eight rats. The rats were killed 72 h after the modeling, the blood supernatant and kidneys were collected, and then the serum creatinine and blood urea nitrogen levels were measured; HE staining was used to observe the pathological changes in kidney tissue; TUNEL was used to detect apoptosis level in renal tubular epithelial cells; frozen section was used to observe the expression of ROS in renal tissue by reactive oxygen staining; the expression of NLRP3, ASC, caspase-1, IL-1β, IL-18 were detected by immunohistochemistry and western blot. RESULTS: The CI-AKI rat model was induced by iohexol. Then the elevated level of ROS activated the inflammatory response mediated by NLRP3 inflammasome (NLRP3, ASC, caspase-1). Subsequently, the increase in renal tubular epithelial cell apoptosis caused the destruction of the pathological structure of the kidney and finally led to renal impairment. While after the pretreatment of astaxanthin, the level of ROS was decreased. The activation level of NLRP3 inflammasome and its mediated inflammatory response were alleviated significantly. Eventually, the level of renal tubular epithelial cell apoptosis and renal damage were significantly mitigated. CONCLUSION: Astaxanthin can protect the kidney in CI-AKI by inhibiting the activation of NLRP3 inflammasome-IL-1β/IL-18 through inhibition of the production of ROS.
OBJECTIVE: To explore the protective effect and mechanism of astaxanthin on the kidney of rats with contrast-induced acute kidney injury. METHODS: Forty SD rats were randomly divided into five groups: Control group (CON); Astaxanthin control group (AST); Contrast media group (CM); Astaxanthin pre-treatment group (AST + CM); N-acetylcysteine pre-treatment group (NAC + CM), each group with eight rats. The rats were killed 72 h after the modeling, the blood supernatant and kidneys were collected, and then the serum creatinine and blood urea nitrogen levels were measured; HE staining was used to observe the pathological changes in kidney tissue; TUNEL was used to detect apoptosis level in renal tubular epithelial cells; frozen section was used to observe the expression of ROS in renal tissue by reactive oxygen staining; the expression of NLRP3, ASC, caspase-1, IL-1β, IL-18 were detected by immunohistochemistry and western blot. RESULTS: The CI-AKI rat model was induced by iohexol. Then the elevated level of ROS activated the inflammatory response mediated by NLRP3 inflammasome (NLRP3, ASC, caspase-1). Subsequently, the increase in renal tubular epithelial cell apoptosis caused the destruction of the pathological structure of the kidney and finally led to renal impairment. While after the pretreatment of astaxanthin, the level of ROS was decreased. The activation level of NLRP3 inflammasome and its mediated inflammatory response were alleviated significantly. Eventually, the level of renal tubular epithelial cell apoptosis and renal damage were significantly mitigated. CONCLUSION: Astaxanthin can protect the kidney in CI-AKI by inhibiting the activation of NLRP3 inflammasome-IL-1β/IL-18 through inhibition of the production of ROS.
Authors: Peter A McCullough; Andy Adam; Christoph R Becker; Charles Davidson; Norbert Lameire; Fulvio Stacul; James Tumlin Journal: Am J Cardiol Date: 2006-02-23 Impact factor: 2.778
Authors: Somjot S Brar; Vicken Aharonian; Prakash Mansukhani; Naing Moore; Albert Y-J Shen; Michael Jorgensen; Aman Dua; Lindsay Short; Kevin Kane Journal: Lancet Date: 2014-05-24 Impact factor: 79.321
Authors: Roxana Mehran; Eve D Aymong; Eugenia Nikolsky; Zoran Lasic; Ioannis Iakovou; Martin Fahy; Gary S Mintz; Alexandra J Lansky; Jeffrey W Moses; Gregg W Stone; Martin B Leon; George Dangas Journal: J Am Coll Cardiol Date: 2004-10-06 Impact factor: 24.094
Authors: Ramez Morcos; Michael Kucharik; Pirya Bansal; Haider Al Taii; Rupesh Manam; Joel Casale; Houman Khalili; Brijeshwar Maini Journal: Clin Med Insights Cardiol Date: 2019-11-01